Cover image of cerliponase alfa outcome statement


Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
26 October 2020
Last updated: 
3 February 2021
Publication type: 
Intended audience: 
General public

This document summarises the Life Saving Drugs Program Expert Panel's consideration of BioMarin's application to include cerliponase alfa (Brineura®) on the Life Saving Drugs Program for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.

The document contains:

  • Overview
  • Background
  • PBAC consideration
  • Consumer input
  • LSDP Expert Panel consideration
  • Treatment guidelines
  • Context
  • Sponsor’s comment.